Arrowhead Pharmaceuticals

ARWRApproved

Pasadena, United StatesFounded 1989arrowheadpharma.com

Arrowhead Pharmaceuticals leverages RNA interference (RNAi) technology through their Targeted RNAi Molecule (TRiM™) platform to develop therapeutics that silence genes causing disease. With over a decade of experience in RNAi-based therapies, the company has advanced multiple programs across cardiometabolic, liver, and pulmonary diseases. Their lead asset Plozasiran has achieved commercial approval for FCS and is advancing in Phase 3 trials for severe hypertriglyceridemia, demonstrating the platform's potential to address significant unmet medical needs.

Market Cap

$7.9B

Founded

1989

Focus

RNA & Gene Therapy

ARWR · Stock Price

USD 56.33+12.22 (+27.70%)

Historical price data

AI Company Overview

Technology Platform

Arrowhead's TRiM™ (Targeted RNAi Molecule) platform leverages RNA interference to silence disease-causing genes through ligand-mediated delivery, enabling tissue-specific targeting with simplified manufacturing and multiple administration routes.

Pipeline Snapshot

52 drugs in pipeline, 9 in Phase 3

Drug	Indication	Stage
Zodasiran	Homozygous Familial Hypercholesterolemia	Phase 3
zodasiran Injection + Placebo	Homozygous Familial Hypercholesterolemia	Phase 3
Plozasiran + Placebon	Familial Chylomicronemia Syndrome	Phase 3
Plozasiran + Placebo	Severe Hypertriglyceridemia	Phase 3
Plozasiran Injection + Placebo	Hypertriglyceridemia	Phase 3

FDA Approved Drugs

REDEMPLONDANov 18, 2025

Opportunities

Significant expansion potential with Phase 3 plozasiran trials for severe hypertriglyceridemia, diverse pipeline across high-value therapeutic areas, and platform capability to target tissues beyond liver.

Goal to achieve 20 products in clinical trials or on market by 2025 provides substantial growth runway.

Risk Factors

Clinical development risks across multiple early-stage programs, competitive pressure in RNAi therapeutics space, manufacturing scale-up challenges, and regulatory approval complexities for novel platform across diverse indications.

Competitive Landscape

Competes with Alnylam Pharmaceuticals and other RNAi companies, differentiated by TRiM™ platform's tissue-specific targeting beyond liver and simplified manufacturing approach. Platform versatility provides competitive advantage in addressing broader therapeutic opportunities.

Publications

Patents

Pipeline

FDA Approvals